The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

Long-Term Outcomes Reinforce the High Efficacy of Biktarvy ® in People with HIV and HBV Coinfection – – Investigational Long-Acting, Twice-Yearly Treatment Regimen of Len ...

NIH-sponsored trial data offer further evidence to help inform mpox treatment decisions. Colorized transmission electron micrograph of immature mpox virus particles (blue with red viral envelope) ...

The college’s Visualizing Science competition finalists include the winning image of a Logistic Map’s Chaotic Portion by an ...

Damage or injury to nerves causes a painful condition called neuropathy. This article reviews the safety and evidence behind ...

It is, somehow, the fifth anniversary of the COVID pandemic – more on that below, along with new violence in Syria and Loblaw ...

Certain unregistered supplements may interfere with the absorption or metabolism of chemotherapy drugs, increasing the risk ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...